Screener
Novavax NVAX Deferred Revenue
Deferred Revenue at other companies
Other financials
Where this comes from
Reported directly by Novavax in its filing.
Tagged under the XBRL concept us-gaap:ContractWithCustomerLiabilityCurrent.
The source filing: Novavax’s 10-Q, filed August 6, 2026. Open the filing →
- Filed
- Aug 6, 2026, 7:50 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001000694-26-000018
FAQ
- What is Novavax's deferred revenue?
- Novavax (NVAX) reported deferred revenue of $86.58M in Q2 2026.
- How has Novavax's deferred revenue changed year-over-year?
- Novavax's deferred revenue decreased by 23.9% year-over-year, from $113.76M to $86.58M.
- What is the long-term trend for Novavax's deferred revenue?
- Over 5 years (2020 to 2025), Novavax's deferred revenue has grown at a -14.1% compound annual growth rate (CAGR), from $300M to $140.05M.
- What does deferred revenue mean?
- Payments received from customers for goods or services to be delivered within one year — recognized as revenue as performance obligations are satisfied.
Ask your AI about Novavax's deferred revenue.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude